再生元制药公司宣布,其Cemdisiran单药疗法采用每三个月皮下给药一次的给药方案,在临床试验中成功达到了主要终点和关键次要终点。
再生元制药公司宣布,其Cemdisiran单药疗法采用每三个月皮下给药一次的给药方案,在临床试验中成功达到了主要终点和关键次要终点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.